Lung Transplant Pathology
• The diagnosis of rejection is one of exclusion; infection and other lesions must be ruled out.
• At least 5 pieces of alveolar parenchyma are necessary for a reliable diagnosis.
• At least 3 h&e stained slides from 3 levels in the block and trichrome (connective tissue) stain must be reviewed.
Lung Transplant Pathology: Revised ISHLT grading One month after beginning therapy, she complained of cough and shortness of breath. She was found to be neutropenic and was begun on antibiotic therapy (vancomycin) for presumed pneumonia.
A. Acute Rejection
Her neutropenia improved, but her cough and breathlessness progressed. She was begun on azythromycin and bronchodilators without improvement.
A surgical lung biopsy was performed. Rituximab is a murine monoclonal antibody directed against CD20. FDA indications include relapsed (or refractory) low grade or follicular, CD20 positive B cell lymphomas. May be used in combination therapy with other agents in higher grade CD20 positive lymphomas.
Pulmonary toxicity related to rituximab is reported but uncommon.
Interstitial pneumonia associated with rituximab may be severe. Jullien V, et al: Rev Mal Respir. 2004 Apr; 21(2 Pt 1):407-10 The spectrum of subsequent disease The past medical history is remarkable for CML diagnosed 7 years earlier and treated with allogeneic bone marrow transplantation from a living related donor.
The intervening years were punctuated by CNS toxoplasmosis and graft-versus-host disease (skin and GI tract). The FEV1 on admission was 46%. The patient also complained of decreased exercise tolerance and unintentional weightloss. Chest imaging initially revealed a slightly nodular peripheral infiltrate and this progressed over the subsequent three weeks to involve predominately mid and lower lung zones bilaterally, with minimal upper lobe infiltrates.
He was treated with aerosolized ribaviran, but his infiltrates progressed. 
